Preclinical and clinical studies demonstrate GLP-1 RAs’ cardioprotective effects, efficacy in hypertension and dyslipidemia, substantial weight loss in diabetes and obesity, and neuroprotective roles in stroke and neurodegenerative diseases. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.